1. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV.
- Author
-
Sun, Cong, Kang, Yin-Feng, Fang, Xin-Yan, Liu, Yi-Na, Bu, Guo-Long, Wang, Ao-Jie, Li, Yan, Zhu, Qian-Ying, Zhang, Hua, Xie, Chu, Kong, Xiang-Wei, Peng, Yong-Jian, Lin, Wen-Jie, Zhou, Ling, Chen, Xin-Chun, Lu, Zheng-Zhou, Xu, Hui-Qin, Hong, Dong-Chun, Zhang, Xiao, and Zhong, Ling
- Abstract
Epstein-Barr virus (EBV) is a global public health concern, as it is known to cause multiple diseases while also being etiologically associated with a wide range of epithelial and lymphoid malignancies. Currently, there is no available prophylactic vaccine against EBV. gB is the EBV fusion protein that mediates viral membrane fusion and participates in host recognition, making it critical for EBV infection in both B cells and epithelial cells. Here, we present a gB nanoparticle, gB-I53-50 NP, that displays multiple copies of gB. Compared with the gB trimer, gB-I53-50 NP shows improved structural integrity and stability, as well as enhanced immunogenicity in mice and non-human primate (NHP) preclinical models. Immunization and passive transfer demonstrate a robust and durable protective antibody response that protects humanized mice against lethal EBV challenge. This vaccine candidate demonstrates significant potential in preventing EBV infection, providing a possible platform for developing prophylactic vaccines for EBV. [Display omitted] • An EBV gB nanoparticle, gB-I53-50 NP, shows enhanced stability and antigenicity • gB-I53-50 NP elicits robust, potent, and durable protective antibodies in mice and NHPs • Passive transfer from gB-I53-50-NP-immunized NHPs confers protection to humanized mice An effective EBV vaccine is urgently needed but remains elusive. Sun et al. present a gB nanoparticle vaccine with enhanced stability and immunogenicity that elicits robust and durable protective antibodies in preclinical models. Immunization of humanized mice prevents lethal EBV infection, thereby offering a potential strategy for EBV vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF